CN104768543A - 用于使用蝶芪诱导udp-葡萄糖醛酸转移酶活性的方法 - Google Patents

用于使用蝶芪诱导udp-葡萄糖醛酸转移酶活性的方法 Download PDF

Info

Publication number
CN104768543A
CN104768543A CN201280074486.2A CN201280074486A CN104768543A CN 104768543 A CN104768543 A CN 104768543A CN 201280074486 A CN201280074486 A CN 201280074486A CN 104768543 A CN104768543 A CN 104768543A
Authority
CN
China
Prior art keywords
methods
ugt
carcinoma
pterostibene
pterostilbene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280074486.2A
Other languages
English (en)
Chinese (zh)
Inventor
J·巴托斯
瑞安·德林杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chromadex Inc
University of California San Diego UCSD
Original Assignee
Chromadex Inc
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromadex Inc, University of California San Diego UCSD filed Critical Chromadex Inc
Publication of CN104768543A publication Critical patent/CN104768543A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CN201280074486.2A 2012-05-08 2012-11-14 用于使用蝶芪诱导udp-葡萄糖醛酸转移酶活性的方法 Pending CN104768543A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/466,827 US8841350B2 (en) 2011-05-11 2012-05-08 Method for inducing UDP-glucuronosyltransferase activity using pterostilbene
US13/466,827 2012-05-08
PCT/US2012/064993 WO2013169291A2 (en) 2012-05-08 2012-11-14 Method for inducing udp-glucuronosyltransferase activity using pterostilbene

Publications (1)

Publication Number Publication Date
CN104768543A true CN104768543A (zh) 2015-07-08

Family

ID=47142275

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280074486.2A Pending CN104768543A (zh) 2012-05-08 2012-11-14 用于使用蝶芪诱导udp-葡萄糖醛酸转移酶活性的方法

Country Status (12)

Country Link
US (2) US8841350B2 (https=)
EP (1) EP2846785A4 (https=)
JP (1) JP2015523963A (https=)
KR (1) KR20150027081A (https=)
CN (1) CN104768543A (https=)
AU (1) AU2012379655B2 (https=)
BR (1) BR112014027646A2 (https=)
CA (1) CA2872623A1 (https=)
IN (1) IN2014DN09990A (https=)
MX (1) MX2014013503A (https=)
WO (1) WO2013169291A2 (https=)
ZA (1) ZA201408893B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106877A (zh) * 2014-09-04 2017-08-29 加利福尼亚大学董事会 用于治疗uv诱发的皮肤屏障功能受损的局部用蝶芪组合物
US20160067193A1 (en) * 2014-09-04 2016-03-10 The Regents Of The University Of California Topical pterostilbene compositions for use in treating uv-induced skin damage and hyperplasia
JP2018517774A (ja) 2015-06-10 2018-07-05 エリジウム・ヘルス・インコーポレイテッド ニコチンアミドリボシドおよびプテロスチルベン組成物ならびに皮膚障害の処置のための方法
US12134956B2 (en) 2022-10-11 2024-11-05 Halliburton Energy Services, Inc. Liner hanger system
US12398624B2 (en) 2023-07-11 2025-08-26 Halliburton Energy Services, Inc. Self-energizing seal for expandable liner hanger
US12509957B1 (en) 2024-09-16 2025-12-30 Halliburton Energy Services, Inc. Partially bonded seals for well systems

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175803A1 (en) * 2008-01-08 2009-07-09 David Rubin Method and compositions for administering resveratrol and pterostilbene
WO2011042482A1 (en) * 2009-10-06 2011-04-14 Green Molecular Polyphenols for use in the treatment of cancer
WO2011051483A1 (en) * 2009-10-30 2011-05-05 Green Molecular, S.L Pterostilbene (pter) for use in the prevention and/or treatment of skin diseases, damages or injures
WO2011097372A2 (en) * 2010-02-03 2011-08-11 Aptuit Laurus Private Limited Pterostilbene cocrystals

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6623724B2 (en) * 1996-09-18 2003-09-23 Applied Genetics Incorporated Dermatics Dermatological compositions and methods
US6414037B1 (en) * 1998-01-09 2002-07-02 Pharmascience Pharmaceutical formulations of resveratrol and methods of use thereof
DE10161253A1 (de) 2001-12-13 2003-06-26 Dragoco Gerberding Co Ag Verwendung von Dihydropinosylvin und dessen Derivaten als Inhibitoren
FR2869229B1 (fr) 2004-04-26 2006-08-25 Sederma Soc Par Actions Simpli Utilisation d'un inducteur des ugt par voie topique
ES2246165B1 (es) 2004-07-20 2006-12-01 Universitat De Valencia Uso combinado del pteroestilbeno y la quercetina para la fabricacion de medicamentos utiles en el tratamiento del cancer.
WO2008070872A1 (en) 2006-12-07 2008-06-12 Rutgers, The State University Of New Jersey Prevention and treatment of colon cancer
US8509879B2 (en) 2007-11-06 2013-08-13 The Regents Of The University Of California Apparatus and method for widefield functional imaging (WiFI) using integrated structured illumination and laser speckle imaging
US20090324740A1 (en) 2008-06-13 2009-12-31 Albritton Iv Ford D Novel nasal spray
US20100240767A1 (en) 2009-03-23 2010-09-23 Muhammed Majeed Melanogenesis inhibitiuon by 3,5-dimethoxy-4'-hydroxystilbenes and cosmeceutical compositions thereof
US9737495B2 (en) 2009-06-22 2017-08-22 Indus Biotech Private Limited Process for obtaining purified pterostilbene and methods of use thereof
US8883218B2 (en) * 2010-03-26 2014-11-11 The Board Of Trustees Of The University Of Arkansas Anti-cancer nanoparticle compositions and methods of use
MX344772B (es) 2011-01-28 2017-01-06 Univ Kentucky Res Found Analogos de estilbeno y metodos para tratar cancer.
JP6155191B2 (ja) * 2011-10-02 2017-06-28 キユーピー株式会社 ＲＮＡ干渉によるｍＲＮＡ発現の抑制を促進する促進剤およびその用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175803A1 (en) * 2008-01-08 2009-07-09 David Rubin Method and compositions for administering resveratrol and pterostilbene
WO2011042482A1 (en) * 2009-10-06 2011-04-14 Green Molecular Polyphenols for use in the treatment of cancer
WO2011051483A1 (en) * 2009-10-30 2011-05-05 Green Molecular, S.L Pterostilbene (pter) for use in the prevention and/or treatment of skin diseases, damages or injures
WO2011097372A2 (en) * 2010-02-03 2011-08-11 Aptuit Laurus Private Limited Pterostilbene cocrystals

Also Published As

Publication number Publication date
JP2015523963A (ja) 2015-08-20
KR20150027081A (ko) 2015-03-11
US8841350B2 (en) 2014-09-23
IN2014DN09990A (https=) 2015-08-14
CA2872623A1 (en) 2013-11-14
US10039725B2 (en) 2018-08-07
ZA201408893B (en) 2016-08-31
EP2846785A4 (en) 2016-06-15
AU2012379655A1 (en) 2014-11-20
EP2846785A2 (en) 2015-03-18
WO2013169291A3 (en) 2015-06-18
AU2012379655B2 (en) 2018-01-18
BR112014027646A2 (pt) 2017-06-27
MX2014013503A (es) 2015-11-13
WO2013169291A2 (en) 2013-11-14
US20150011650A1 (en) 2015-01-08
US20120289605A1 (en) 2012-11-15

Similar Documents

Publication Publication Date Title
Bowden Prevention of non-melanoma skin cancer by targeting ultraviolet-B-light signalling
US9308192B2 (en) Use of NRF2 inducers to treat epidermolysis bullosa simplex and related diseases
Keum et al. Inhibitory effects of the ginsenoside Rg3 on phorbol ester-induced cyclooxygenase-2 expression, NF-κB activation and tumor promotion
Palliyaguru et al. Withaferin A induces Nrf2-dependent protection against liver injury: Role of Keap1-independent mechanisms
Yajima et al. Isohumulones, bitter acids derived from hops, activate both peroxisome proliferator-activated receptor α and γ and reduce insulin resistance
US10039725B2 (en) Method for treating non-melanoma skin cancer by inducing UDP-glucuronosyltransferase activity using pterostilbene
Luo et al. The role of COX-2 and Nrf2/ARE in anti-inflammation and antioxidative stress: Aging and anti-aging
Chen et al. Selenoprotein P is elevated in individuals with obesity, but is not independently associated with insulin resistance
Takemura et al. S-Allyl cysteine improves nonalcoholic fatty liver disease in type 2 diabetes Otsuka Long-Evans Tokushima Fatty rats via regulation of hepatic lipogenesis and glucose metabolism
Sampath et al. Activation of Nrf2 attenuates delayed gastric emptying in obesity induced diabetic (T2DM) female mice
Takahashi et al. Apo-12′-lycopenal, a lycopene metabolite, promotes adipocyte differentiation via peroxisome proliferator-activated receptor γ activation
CA3153879A1 (en) Curcuminoid composition for therapeutic management of metabolic syndrome
Chevillard et al. Nrf3-deficient mice are not protected against acute lung and adipose tissue damages induced by butylated hydroxytoluene
JP2007517836A (ja) 局所適用の脱色素組成物及び類似の組成物の調整でのイデベノンの使用
Lương et al. The roles of vitamin D in seborrhoeic keratosis: possible genetic and cellular signalling mechanisms
He et al. The effect of PPARγ ligands on UV‐or chemically‐induced carcinogenesis in mouse skin
Barbagallo et al. The effects of olive leaf extract from a Sicilian cultivar in an experimental model of hepatic steatosis
Jahan et al. 5-Fluorouracil and Sesamol loaded transliposome gel for skin cancer: Pre-clinical evaluation in UV induced mice model
Romo-Robles et al. Effects of a Diet Supplemented with Fruit Antioxidants (Mango) on the Expression of Kir6. 2 (KCNJ11) in the Hippocampus and Kidney of Diabetic Rats
Takahashi et al. Inhibitory effects of p-alkylaminophenol on melanogenesis
Abdull Razis et al. Characterization of the temporal induction of hepatic xenobiotic-metabolizing enzymes by glucosinolates and isothiocyanates: Requirement for at least a 6 h exposure to elicit complete induction profile
Lluria-Prevatt et al. Skin cancer prevention
US12233032B2 (en) Compositions for management of polycystic ovary syndrome
Taïeb et al. ooInhibitors and enhancers of melanogenesis
Kshatriya In Vivo Effects of Raspberry Ketone (4-(4-Hydroxyphenyl)-Butan-2-One) as a Supplement for Weight Loss in Mice

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150708

WD01 Invention patent application deemed withdrawn after publication